11 results on '"Gavilán, Sergi"'
Number of results to display per page
Search Results
2. Yaws recurrence in children at continued risk of infection
- Author
-
Beiras, Camila G., primary, Marks, Michael, additional, Quintó, Llorenç, additional, Gavilán, Sergi, additional, Kolmau, Reman, additional, Ubals, Maria, additional, Vall-Mayans, Marti, additional, and Mitjà, Oriol, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial
- Author
-
0000-0002-8132-5645, Mitjà, Oriol, Corbacho-Monné, Marc, Ubals, Maria, Tebé, Cristian, Peñafiel, Judith, Tobías, Aurelio, Ballana, Ester, Alemany, Andrea, Riera-Martí, Núria, Pérez, Carla A, Suñer, Clara, Laporte, Pep, Admella, Pol, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, Argimon, Josep M, Casabona, Jordi, Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Nieto, Aroa, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Reyes-Ureña, Juliana, Ramírez-Viaplana, Ferran, Ruiz, Lidia, Riveira-Muñoz, Eva, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa M., Sentís, Alexis, G-Beiras, Camila, Clotet, Bonaventura, Vall-Mayans, Martí, 0000-0002-8132-5645, Mitjà, Oriol, Corbacho-Monné, Marc, Ubals, Maria, Tebé, Cristian, Peñafiel, Judith, Tobías, Aurelio, Ballana, Ester, Alemany, Andrea, Riera-Martí, Núria, Pérez, Carla A, Suñer, Clara, Laporte, Pep, Admella, Pol, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, Argimon, Josep M, Casabona, Jordi, Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Nieto, Aroa, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Reyes-Ureña, Juliana, Ramírez-Viaplana, Ferran, Ruiz, Lidia, Riveira-Muñoz, Eva, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa M., Sentís, Alexis, G-Beiras, Camila, Clotet, Bonaventura, and Vall-Mayans, Martí
- Abstract
No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19.
- Published
- 2021
4. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
- Author
-
Mitjà, Oriol, primary, Corbacho-Monné, Marc, additional, Ubals, Maria, additional, Alemany, Andrea, additional, Suñer, Clara, additional, Tebé, Cristian, additional, Tobias, Aurelio, additional, Peñafiel, Judith, additional, Ballana, Ester, additional, Pérez, Carla A., additional, Admella, Pol, additional, Riera-Martí, Núria, additional, Laporte, Pep, additional, Mitjà, Jordi, additional, Clua, Mireia, additional, Bertran, Laia, additional, Sarquella, Maria, additional, Gavilán, Sergi, additional, Ara, Jordi, additional, Argimon, Josep M., additional, Cuatrecasas, Gabriel, additional, Cañadas, Paz, additional, Elizalde-Torrent, Aleix, additional, Fabregat, Robert, additional, Farré, Magí, additional, Forcada, Anna, additional, Flores-Mateo, Gemma, additional, López, Cristina, additional, Muntada, Esteve, additional, Nadal, Núria, additional, Narejos, Silvia, additional, Nieto, Aroa, additional, Prat, Nuria, additional, Puig, Jordi, additional, Quiñones, Carles, additional, Ramírez-Viaplana, Ferran, additional, Reyes-Urueña, Juliana, additional, Riveira-Muñoz, Eva, additional, Ruiz, Lidia, additional, Sanz, Sergi, additional, Sentís, Alexis, additional, Sierra, Alba, additional, Velasco, César, additional, Vivanco-Hidalgo, Rosa M., additional, Zamora, Juani, additional, Casabona, Jordi, additional, Vall-Mayans, Martí, additional, González-Beiras, Camila, additional, and Clotet, Bonaventura, additional
- Published
- 2021
- Full Text
- View/download PDF
5. A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease
- Author
-
Mitjà, Oriol, primary, Ubals, Maria, additional, Corbacho-Monné, Marc, additional, Alemany, Andrea, additional, Suñer, Clara, additional, Tebe, Cristian, additional, Tobias, Aurelio, additional, Peñafiel, Judith, additional, Ballana, Ester, additional, Pérez, Carla A., additional, Admella, Pol, additional, Riera-Martí, Nuria, additional, Laporte, Pep, additional, Mitja, Jordi, additional, Clua, Mireia, additional, Bertran, Laia, additional, Sarquella, Maria, additional, Gavilán, Sergi, additional, Ara, Jordi, additional, Argimon, Josep M, additional, Cuatrecasas, Gabriel, additional, Cañadas, Paz, additional, Elizalde-Torrent, Aleix, additional, Fabregat, Robert, additional, Farré, Magí, additional, Forcada, Anna, additional, Flores-Mateo, Gemma, additional, López, Cristina, additional, Muntada, Esteve, additional, Nadal, Núria, additional, Narejos, Silvia, additional, Gil-Ortega, Aroa N, additional, Prat, Nuria, additional, Puig, Jordi, additional, Quiñones, Carles, additional, Ramírez-Viaplana, Ferran, additional, Urueña, Juliana Reyes-, additional, Riveira-Muñoz, Eva, additional, Ruiz, Lidia, additional, Sanz, Sergi, additional, Sentis, Alexis, additional, Sierra, Alba, additional, Velasco, César, additional, Vivanco-Hidalgo, Rosa Maria, additional, Zamora, Juani, additional, Casabona, Jordi, additional, Vall-Mayans, Martí, additional, G-Beiras, Camila, additional, and Clotet, Bonaventura, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial
- Author
-
Mitjà, Oriol, primary, Corbacho-Monné, Marc, additional, Ubals, Maria, additional, Tebé, Cristian, additional, Peñafiel, Judith, additional, Tobias, Aurelio, additional, Ballana, Ester, additional, Alemany, Andrea, additional, Riera-Martí, Núria, additional, Pérez, Carla A, additional, Suñer, Clara, additional, Laporte, Pep, additional, Admella, Pol, additional, Mitjà, Jordi, additional, Clua, Mireia, additional, Bertran, Laia, additional, Sarquella, Maria, additional, Gavilán, Sergi, additional, Ara, Jordi, additional, Argimon, Josep M, additional, Casabona, Jordi, additional, Cuatrecasas, Gabriel, additional, Cañadas, Paz, additional, Elizalde-Torrent, Aleix, additional, Fabregat, Robert, additional, Farré, Magí, additional, Forcada, Anna, additional, Flores-Mateo, Gemma, additional, Muntada, Esteve, additional, Nadal, Núria, additional, Narejos, Silvia, additional, Nieto, Aroa, additional, Prat, Nuria, additional, Puig, Jordi, additional, Quiñones, Carles, additional, Reyes-Ureña, Juliana, additional, Ramírez-Viaplana, Ferran, additional, Ruiz, Lidia, additional, Riveira-Muñoz, Eva, additional, Sierra, Alba, additional, Velasco, César, additional, Vivanco-Hidalgo, Rosa Maria, additional, Sentís, Alexis, additional, G-Beiras, Camila, additional, Clotet, Bonaventura, additional, and Vall-Mayans, Martí, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Yaws recurrence in children at continued risk of infection.
- Author
-
González-Beiras, Camila, Marks, Michael, Quintó, Llorenç, Gavilán, Sergi, Kolmau, Reman, Ubals, Maria, Vall-Mayans, Marti, and Mitjà, Oriol
- Subjects
BURULI ulcer ,SYPHILIS ,HEALTH facilities ,ELECTRONIC health records ,NEGLECTED diseases ,SERODIAGNOSIS ,WATCHFUL waiting - Abstract
Background: In yaws-endemic areas, children with Treponema pallidum subsp. pertenue infection may suffer recurrent episodes due to either reinfection or relapse. However, the possibility of infection with other cutaneous ulcer causative agents and difficulties in interpreting standard laboratory results challenges the estimation of yaws recurrence rates. Methods: We estimated the rates of yaws recurrences in the Lihir Island (Papua New Guinea) using two approaches: passive surveillance based on a retrospective screening of electronic medical records of cutaneous ulcers diagnosed using serological testing between 2005 and 2016, and active surveillance conducted during a cross-sectional prevalence study which included PCR analyses of ulcers of all suspected cases of yaws. The risk of recurrent infection was assessed based on data from the passive surveillance analysis and using two Cox regression models (crude and multivariate), stratified by year of index episode. Data gathered from the active surveillance was used to characterize the recurrences and no hypothesis testing was performed. Results: The electronic medical records included 6,125 patients (7,889 ulcer episodes) with documented serological results of cutaneous ulcers of which1,486 were diagnosed with yaws. Overall, 1,246/6,125 patients (20.3%) presented more than once with a cutaneous ulcer, and 103/1,486 (6.7%) patients had multiple episodes of yaws. The risk of yaws recurrence significantly increased with age and was higher in patients with ≥3 recurrent episodes. In the active surveillance, we identified 50 individuals with recurrent cutaneous ulcer that had PCR results available for both the index and recurrent episode. Of 12 individuals with T. pallidum in the index ulcer, 8 (66%) had T. pallidum in subsequent assessments, relapse related to macrolide-resistance was identified in two of these cases. Conclusions: Our results confirm the need for active follow-up of yaws patients after treatment, particularly children and individuals with a history of recurrence. Author summary: Yaws is a neglected tropical disease produced by Treponema pallidum pertenue that causes skin ulcers in children living in remote rural areas of the South Pacific and West Africa. Children aged 5–15 and individuals with a history of recurrence are at higher risk of reinfection. Although yaws can be treated with single-dose azithromycin, some children present with recurrent cutaneous ulcers; however, the prevalence and risk factors for yaws recurrence are poorly known. Our analysis of skin ulcers in Papua New Guinea revealed that up to 20% of patients who presented to a health care facility in the Lihir island of Papua New Guinea with a cutaneous ulcer experienced a recurrent episode within the 6–36 months following treatment. Nearly all individuals with recurrent yaws were children aged 15 years or younger. Besides age, the number of previous ulcers was associated with a higher risk of recurrence. The molecular analysis revealed that among cases with T. pallidum at baseline that had a recurrence, this was often related to reinfection with the same microorganism. Our results confirm the need for active follow-up of young children diagnosed with cutaneous ulcers, with particular attention to those with younger age and previous history of recurrences. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease
- Author
-
YoMeCorono, Laboratorios Rubió, Gebro Pharma, Zurich Seguros, SYNLAB, Generalitat de Catalunya, Mitjà, Oriol, Ubals, Maria, Corbacho, Marc, Alemany, Andrea, Suñer, Clara, Tebé, Cristian, Tobías, Aurelio, Peñafiel, Judith, Ballana, Ester, Pérez, Carla, Admella, Pol, Riera-Martí, Núria, Laporte, Pep, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, Argimon, Josep M., Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, López, Cristina, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Gil-Ortega, Aroa, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Ramírez-Vilaplana, Ferrán, Reyes-Urueña, Juliana, Riveira-Muñoz, Eva, Ruiz, Lidia, Sanz, Sergi, Sentís, Alexis, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa M., Zamora, Juani, Casabona, Jordi, Vall-Mayans, Martí, G-Beiras, Camila, Clotet, Bonaventura, YoMeCorono, Laboratorios Rubió, Gebro Pharma, Zurich Seguros, SYNLAB, Generalitat de Catalunya, Mitjà, Oriol, Ubals, Maria, Corbacho, Marc, Alemany, Andrea, Suñer, Clara, Tebé, Cristian, Tobías, Aurelio, Peñafiel, Judith, Ballana, Ester, Pérez, Carla, Admella, Pol, Riera-Martí, Núria, Laporte, Pep, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, Argimon, Josep M., Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, López, Cristina, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Gil-Ortega, Aroa, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Ramírez-Vilaplana, Ferrán, Reyes-Urueña, Juliana, Riveira-Muñoz, Eva, Ruiz, Lidia, Sanz, Sergi, Sentís, Alexis, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa M., Zamora, Juani, Casabona, Jordi, Vall-Mayans, Martí, G-Beiras, Camila, and Clotet, Bonaventura
- Abstract
Background Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been proposed as a postexposure therapy to prevent Coronavirus disease 2019 (Covid-19) but definitive evidence is lacking. Methods We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms. Adverse events (AEs) were assessed up to 28 days. Results The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% HCQ), but no treatment-related serious AEs were reported. Conclusions Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy individuals exposed to a PCR-positive case. Our findings do not support HCQ as postexposure prophylaxis for Covid-19.
- Published
- 2020
9. Hydroxychloroquine Alone or in Combination with Cobicistat-Boosted Darunavir for Treatment of Mild COVID-19: A Cluster-Randomized Clinical Trial
- Author
-
YoMeCorono, Laboratorios Rubió, Gebro Pharma, Zurich Seguros, SYNLAB, Generalitat de Catalunya, Mitjà, Oriol, Corbacho, Marc, G-Beiras, Camila, Tebé, Cristian, Tobías, Aurelio, Ballana, Ester, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ubals, Maria, Alemany, Andrea, Riera-Martí, Núria, Suñer, Clara, Álvarez, Carla, Laporte, Pep, Admella, Pol, Ara, Jordi, Argimon, Josep M., Casabona, Jordi, Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Nieto, Aroa, Peñafiel, Judith, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Reyes-Urueña, Juliana, Ramírez-Vilaplana, Ferrán, Ruiz, Lidia, Riveira-Muñoz, Eva, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa M., Sentís, Alexis, Clotet, Bonaventura, Vall-Mayans, Martí, YoMeCorono, Laboratorios Rubió, Gebro Pharma, Zurich Seguros, SYNLAB, Generalitat de Catalunya, Mitjà, Oriol, Corbacho, Marc, G-Beiras, Camila, Tebé, Cristian, Tobías, Aurelio, Ballana, Ester, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ubals, Maria, Alemany, Andrea, Riera-Martí, Núria, Suñer, Clara, Álvarez, Carla, Laporte, Pep, Admella, Pol, Ara, Jordi, Argimon, Josep M., Casabona, Jordi, Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Nieto, Aroa, Peñafiel, Judith, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Reyes-Urueña, Juliana, Ramírez-Vilaplana, Ferrán, Ruiz, Lidia, Riveira-Muñoz, Eva, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa M., Sentís, Alexis, Clotet, Bonaventura, and Vall-Mayans, Martí
- Abstract
Background: No therapeutics have yet been proven effective for the treatment of mild-illness caused by SARS-CoV-2. We assessed the efficacy and safety of hydroxychloroquine (HCQ) alone or in combination with cobicistat-boosted darunavir (DRVc) for treating patients with mild Covid-19. Methods: We conducted a randomized, prospective, controlled, open-label trial in three health regions of Catalonia. After confirmation of a case of Covid-19 disease, we enumerated on a list a ring of the case and all their contacts and randomly assigned the ring to either control or intervention arm on a 1:1 ratio. Here we present the methods concerning eligible index cases, which involved non-hospitalized adult patients with recently confirmed SARS-CoV-2 infection and less than seven days of symptoms. Patients were assigned to receive HCQ (800 mg on day 1, followed by 400 mg once daily for six days) in combination with DRVc (800 mg/150 mg tablets, once daily for seven days) or no antiviral treatment. The protocol was adapted during the course of the trial to use HCQ alone after findings of no benefit of the protease inhibitor lopinavir-ritonavir. Study outcomes were the reduction of viral RNA load in nasopharyngeal swabs and time to clinical improvement within 28 days of follow-up in the per-protocol population. Adverse events were assessed up to 28 days. Findings: Between Mar 17 and Apr 28, 2020, 353 Covid-19 patients met the criteria for the per-protocol analysis: 165 in the control arm and 142 in the intervention arm. The median time from symptom onset to treatment start was 3 days (IQR 2–4). The per-protocol analysis revealed no significant differences in the mean reduction of viral load in nasopharyngeal swabs at day-3 compared to baseline between the control group (-1·28 Log 10 copies/mL, SD 1·68) and the intervention group (-1·47, SD 1·50); difference -0·18 [95% CI -0.59 to 0·22]. The same pattern was observed at day-7 and -14 after treatment. Time to complete alleviation of sy
- Published
- 2020
10. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial.
- Author
-
Mitjà, Oriol, Corbacho-Monné, Marc, Ubals, Maria, Tebé, Cristian, Peñafiel, Judith, Tobias, Aurelio, Ballana, Ester, Alemany, Andrea, Riera-Martí, Núria, Pérez, Carla A, Suñer, Clara, Laporte, Pep, Admella, Pol, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, and Argimon, Josep M
- Subjects
RESEARCH ,COVID-19 ,VIRAL load ,TIME ,MEDICAL cooperation ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,HOSPITAL care ,HYDROXYCHLOROQUINE ,STATISTICAL sampling ,EARLY medical intervention ,EVALUATION ,ADULTS - Abstract
Background No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19. Methods Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed with <5-day of symptom onset were assigned to receive HCQ (800 mg on day 1 followed by 400 mg once daily for 6 days) or usual care. Outcomes were reduction of viral load in nasopharyngeal swabs up to 7 days after treatment start, disease progression up to 28 days, and time to complete resolution of symptoms. Adverse events were assessed up to 28 days. Results A total of 293 patients were eligible for intention-to-treat analysis: 157 in the control arm and 136 in the intervention arm. The mean age was 41.6 years (SD, 12.6), mean viral load at baseline was 7.90 log
10 copies/mL (SD, 1.82), and median time from symptom onset to randomization was 3 days. No differences were found in the mean reduction of viral load at day 3 (−1.41 vs −1.41 log10 copies/mL in the control and intervention arm, respectively) or at day 7 (−3.37 vs −3.44). Treatment did not reduce risk of hospitalization (7.1% control vs 5.9% intervention) nor shorten the time to complete resolution of symptoms (12 days, control vs 10 days, intervention). No relevant adverse events were reported. Conclusions In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. Hydroxychloroquine Alone or in Combination with Cobicistat-Boosted Darunavir for Treatment of Mild COVID-19: A Cluster-Randomized Clinical Trial
- Author
-
Mitjà, Oriol, primary, Corbacho, Marc, additional, G-Beiras, Camila, additional, Tebé, Cristian, additional, Tobias, Aurelio, additional, Ballana, Ester, additional, Mitjà, Jordi, additional, Clua, Mireia, additional, Bertran, Laia, additional, Sarquella, Maria, additional, Gavilán, Sergi, additional, Ubals, Maria, additional, Alemany, Andrea, additional, Riera-Martí, Núria, additional, Suñer, Clara, additional, Álvarez, Carla, additional, Laporte, Pep, additional, Admella, Pol, additional, Ara, Jordi, additional, Argimon, Josep M., additional, Casabona, Jordi, additional, Cuatrecasas, Gabriel, additional, Cañadas, Paz, additional, Elizalde-Torrent, Aleix, additional, Fabregat, Robert, additional, Farré, Magí, additional, Forcada, Anna, additional, Flores-Mateo, Gemma, additional, Muntada, Esteve, additional, Nadal, Núria, additional, Narejos, Silvia, additional, Nieto, Aroa, additional, Peñafiel, Judith, additional, Prat, Nuria, additional, Puig, Jordi, additional, Quiñones, Carles, additional, Reyes-Urueña, Juliana, additional, Ramírez-Vilaplana, Ferran, additional, Ruiz, Lidia, additional, Riveira-Muñoz, Eva, additional, Sierra, Alba, additional, Velasco, César, additional, Vivanco-Hidalgo, Rosa Maria, additional, Sentís, Alexis, additional, Clotet, Bonaventura, additional, and Vall-Mayans, Martí, additional
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.